

N1 Neuraminidase (NA) Protein with N-Terminal Histidine Tag from Influenza Virus, A/Puerto Rico/8/1934 (H1N1), Recombinant from Baculovirus

Catalog No. NR-19235

This reagent is the tangible property of the U.S. Government.

For research use only. Not for use in humans.

Contributor and Manufacturer:

BEI Resources

Product Description:

A recombinant form of the N1 neuraminidase (NA) protein from influenza A virus, A/Puerto Rico/8/1934 (H1N1) was produced in insect cells using a baculovirus expression vector system and purified by nickel affinity chromatography under denaturing conditions. NR-19235 contains the predicted ectodomain coding region of the N1 neuraminidase (NA) protein from influenza A virus, A/Puerto Rico/8/1934 (H1N1) (GenPept: [ABD77678](#)) fused to a synthetic gene segment encoding an N-terminal octa-histidine tag followed by a 43 amino acid tetramerization domain from vasodilator-stimulated phosphoprotein (VASP) and a thrombin cleavage site, as described for the 1918 pandemic virus.^{1,2} The predicted protein sequence is shown in Figure 1. NR-19235 has a theoretical molecular weight of approximately 50.5 kilodaltons. The full-length NA precursor protein is 454 residues and the crystal structure has been solved at 2.50 Å resolution (PDB: [2HTY](#)).³

NR-19235 lots 64123709 and 70041699 were expressed from the same recombinant baculovirus vector as BEI Resources NR-42002, which was purified in the soluble form from cell supernatants and is functionally active.

Material Provided:

Each vial contains approximately 50 to 150 µg of purified recombinant NA protein in buffer. The concentration, expressed as mg per mL, and buffer composition are shown on the Certificate of Analysis.

Packaging/Storage:

NR-19235 was packaged aseptically in cryovials. The product is provided frozen on dry ice and should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized. **Note: NR-19235 is not stable long-term at 4°C.**

Functional Activity:

NR-19235 has not been tested for enzymatic activity. Previous work at BEI Resources indicated that other influenza virus neuraminidases purified under denaturing conditions and refolded by dialysis are not able to cleave the fluorogenic substrate 2'-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (4-MUNANA).⁴

Citation:

Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: N1 Neuraminidase (NA) Protein with N-Terminal Histidine Tag from Influenza Virus, A/Puerto Rico/8/1934 (H1N1), Recombinant from Baculovirus, NR-19235.”

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in Microbiological and Biomedical Laboratories](#). 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see www.cdc.gov/biosafety/publications/bmb15/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Kühnel, K., et al. “The VASP Tetramerization Domain is a Right-Handed Coiled Coil Based on a 15-Residue Repeat.” [Proc. Natl. Acad. Sci. USA](#) 101 (2004): 17027-17032. PubMed: 15569942.

2. Xu, X., et al. "Structural Characterization of the 1918 Influenza Virus H1N1 Neuraminidase." *J. Virol.* 82 (2008): 10493-10501. PubMed: 18715929.
3. Russell, R. J., et al. "The Structure of H5N1 Avian Influenza Neuraminidase Suggests New Opportunities for Drug Design." *Nature* 443 (2006): 45-49. PubMed: 16915235.
4. Wetherall, N. T., et al. "Evaluation of Neuraminidase Enzyme Assays Using Different Substrates to Measure Susceptibility of Influenza Virus Clinical Isolates to Neuraminidase Inhibitors: Report of the Neuraminidase Inhibitor Susceptibility Network." *J. Clin. Microbiol.* 41 (2003): 742-750. PubMed: 12574276.

ATCC® is a trademark of the American Type Culture Collection.



Figure 1: Predicted Protein Sequence

```

1  ADPHHHHHHH HSSSDYSDLQ RVKQELLEEV KKELQKVKEE IIEAFVQELR
51 KRGSLVPRGS PSRSEFVILT GNSSLCPIRG WAIYSKDNSI RIGSKGDVFF
101 IREPFISCSH LECRFFFLTQ GALLNDKHSS GTVKDRSPYR ALMSCPVGEA
151 PSPYNSRFES VAWSASACHD GMGWLTIGIS GPDNGAVAVL KYNGIITETI
201 KSWRKKILRT QESECACVNG SCFTIMTDGP SDGLASYKIF KIEKGKVTKS
251 IELNAPNSHY EECSCYPDTG KVMCVCRDNW HGSNRPWVSF DQNLDYQIGY
301 ICSGVFGDNP RPEDGTGSCG PVYVDGANGV KGFSYRYGNG VWIGRTKSHS
351 SRHGFEMIWD PNGWTETDSK FSVRQDVVAM TDWSGYSGSF VQHPELTGLD
401 CMRPCFWVEL IRGRPKEKTI WTSASSISFC GVNSDTVDWS WPDGAELPFS
451 IDK
    
```

Plasmid-derived amino acids – Residues 1 to 3 and 61 to 66
 Octa-histidine Tag – Residues 4 to 11
 Tetramerization domain – Residues 12 to 54
 Thrombin cleavage sequence – Residues 55 to 60
HA protein – Residues 67 to 453 (represents amino acid residues 68 to 454)